Abstract

The use of somatostatin or somatostatin analogue Octreotide (SMS 221-995) is still in debate in the therapy of acute pancreatitis. A prospective study was done to investigate the clinical effectiveness of Octreotide the long acting somatostatin analogue in the therapy of acute pancreatitis. The study was done between the years 1991 -1995 and the cases were randomised according to one after the other of each following case and by this way two groups were performed. In the total of 30 cases, 15 were the group of Octreotide which was added to conventional therapies as the dose of 100mcgr/day, the other 15 were the control with conventional approaches. Both groups were compared according to Ranson's criteria, blood amylase level pseudocyst and/or abscess formation, hospitalisation time, morbidity and mortality. Statistical analysis was done by "Statistica for Windows Release 4.3. Copyright Statsoft Inc. 1993". Significant values were predicted by student t-test. The statistical analysis revealed that Octreotide, as 100mcgr/day dose, added to conventional therapies has no significant effect in acute pancreatitis (p<0.12, p<0.99, p<0.12, p<0.59 respectively). This effect may be dose dependent.